ArticleEuropean journal of nuclear medicine and molecular imaging2023
Total-body [
Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- From sensitivity gain to clinical decisions: total-body and long-axial-field-of-view PET/CT for diagnosis and image-based management in oncology and systemic disease.Annals of nuclear medicine · 2026Review
- Clinical performance of [European journal of nuclear medicine and molecular imaging · 2026Article
- Clinical added value of LAFOV PET/CT in patients undergoing same-day [18 F]FDG SAFOV PET/CT scans: an initial experience report and explorative study.European journal of nuclear medicine and molecular imaging · 2026Article
- Patlak-PBNT: a simple population-based Patlak model to generate [EJNMMI physics · 2026Article
- The clinical utility of total-body [European journal of nuclear medicine and molecular imaging · 2026Article
- Superiority of long axial field-of-viewEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Global research landscape of PSMA-targeted radiopharmaceuticals: a two-decade multidimensional bibliometric analysis.Japanese journal of radiology · 2026Article
- PSMA-Based Radiopharmaceuticals in Prostate Cancer Theranostics: Imaging, Clinical Advances, and Future Directions.Cancers · 2026Review
- Article
- Long Axial Field-of-view PET: A New Era of Quantitative PET Imaging for Theranostic Applications in Clinic.PET clinics · 2025Review
- Comparison of clinical performance between late and standard total-body [European journal of nuclear medicine and molecular imaging · 2025Article
- Clinical value of [Theranostics · 2025Article
- The superior detection rate of total-body [European journal of nuclear medicine and molecular imaging · 2024Article
- Combined whole-body dynamic and static PET/CT with low-dose [European journal of nuclear medicine and molecular imaging · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThe purpose of this study was to assess whether total-body [
methodsTwo hundred biochemical recurrent prostate cancer patients with similar clinicopathological characteristics were included, of whom 100 patients underwent early total-body [
resultsThe liver SD of the total-body [
conclusionTotal-body [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.